Joseph Catanzaro
Stock Analyst at Piper Sandler
(2.05)
# 2,890
Out of 4,868 analysts
99
Total ratings
39.51%
Success rate
-7.1%
Average return
Main Sectors:
Stocks Rated by Joseph Catanzaro
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IBRX ImmunityBio | Upgrades: Overweight | $4.25 → $5 | $2.84 | +76.06% | 5 | May 20, 2025 | |
| CTMX CytomX Therapeutics | Maintains: Overweight | $2.5 → $5 | $2.11 | +136.97% | 5 | May 15, 2025 | |
| IOVA Iovance Biotherapeutics | Maintains: Neutral | $7.5 → $6 | $2.04 | +194.12% | 10 | Feb 28, 2025 | |
| SDGR Schrödinger | Maintains: Overweight | $50 → $45 | $21.05 | +113.78% | 3 | Feb 27, 2025 | |
| MRUS Merus | Initiates: Overweight | $84 | $52.59 | +59.73% | 1 | Feb 13, 2025 | |
| GILD Gilead Sciences | Maintains: Overweight | $105 → $110 | $108.00 | +1.85% | 5 | Feb 12, 2025 | |
| EXEL Exelixis | Maintains: Overweight | $37 → $38 | $40.74 | -6.73% | 4 | Feb 12, 2025 | |
| KROS Keros Therapeutics | Maintains: Overweight | $40 → $15 | $13.57 | +10.58% | 3 | Jan 17, 2025 | |
| HALO Halozyme Therapeutics | Maintains: Neutral | $52 → $53 | $53.15 | -0.28% | 9 | Jan 10, 2025 | |
| CRDF Cardiff Oncology | Maintains: Overweight | $7 → $10 | $3.02 | +231.13% | 4 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $57 → $70 | $39.93 | +75.31% | 2 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $15 → $2 | $1.69 | +18.34% | 2 | Nov 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $10 → $19 | $1.91 | +894.76% | 5 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $19 | $5.85 | +224.79% | 1 | Oct 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $12 → $15 | $2.33 | +543.78% | 3 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $20 → $3.75 | $0.35 | +958.43% | 2 | Aug 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $36 | $30.00 | +20.00% | 2 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $40 | $6.41 | +524.02% | 5 | Jul 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $15 | $8.33 | +80.07% | 4 | Jun 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $35 | $11.62 | +201.20% | 1 | Jun 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $4.5 | $0.56 | +698.30% | 1 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $26 → $30 | $1.24 | +2,319.35% | 2 | Apr 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $20 | $1.05 | +1,804.76% | 1 | Apr 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $15 → $10 | $2.33 | +329.18% | 4 | Mar 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $18 | $4.80 | +275.00% | 1 | Feb 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $30 → $25 | $1.41 | +1,673.05% | 3 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $15 → $1.75 | $3.05 | -42.62% | 2 | May 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $20 | $22.81 | -12.32% | 1 | Dec 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $25 → $1.5 | $1.00 | +49.99% | 1 | May 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $240 → $200 | $7.48 | +2,573.80% | 2 | Mar 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $35 | $5.25 | +566.67% | 1 | Jun 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $60 | $1.47 | +3,981.63% | 1 | Mar 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $28 → $18 | $2.60 | +592.31% | 3 | Apr 7, 2020 |
ImmunityBio
May 20, 2025
Upgrades: Overweight
Price Target: $4.25 → $5
Current: $2.84
Upside: +76.06%
CytomX Therapeutics
May 15, 2025
Maintains: Overweight
Price Target: $2.5 → $5
Current: $2.11
Upside: +136.97%
Iovance Biotherapeutics
Feb 28, 2025
Maintains: Neutral
Price Target: $7.5 → $6
Current: $2.04
Upside: +194.12%
Schrödinger
Feb 27, 2025
Maintains: Overweight
Price Target: $50 → $45
Current: $21.05
Upside: +113.78%
Merus
Feb 13, 2025
Initiates: Overweight
Price Target: $84
Current: $52.59
Upside: +59.73%
Gilead Sciences
Feb 12, 2025
Maintains: Overweight
Price Target: $105 → $110
Current: $108.00
Upside: +1.85%
Exelixis
Feb 12, 2025
Maintains: Overweight
Price Target: $37 → $38
Current: $40.74
Upside: -6.73%
Keros Therapeutics
Jan 17, 2025
Maintains: Overweight
Price Target: $40 → $15
Current: $13.57
Upside: +10.58%
Halozyme Therapeutics
Jan 10, 2025
Maintains: Neutral
Price Target: $52 → $53
Current: $53.15
Upside: -0.28%
Cardiff Oncology
Dec 13, 2024
Maintains: Overweight
Price Target: $7 → $10
Current: $3.02
Upside: +231.13%
Nov 7, 2024
Maintains: Overweight
Price Target: $57 → $70
Current: $39.93
Upside: +75.31%
Nov 4, 2024
Downgrades: Neutral
Price Target: $15 → $2
Current: $1.69
Upside: +18.34%
Oct 31, 2024
Maintains: Overweight
Price Target: $10 → $19
Current: $1.91
Upside: +894.76%
Oct 7, 2024
Initiates: Overweight
Price Target: $19
Current: $5.85
Upside: +224.79%
Sep 23, 2024
Maintains: Overweight
Price Target: $12 → $15
Current: $2.33
Upside: +543.78%
Aug 19, 2024
Maintains: Overweight
Price Target: $20 → $3.75
Current: $0.35
Upside: +958.43%
Aug 15, 2024
Maintains: Overweight
Price Target: $36
Current: $30.00
Upside: +20.00%
Jul 8, 2024
Maintains: Overweight
Price Target: $40
Current: $6.41
Upside: +524.02%
Jun 14, 2024
Maintains: Overweight
Price Target: $15
Current: $8.33
Upside: +80.07%
Jun 5, 2024
Maintains: Overweight
Price Target: $35
Current: $11.62
Upside: +201.20%
May 16, 2024
Initiates: Overweight
Price Target: $4.5
Current: $0.56
Upside: +698.30%
Apr 25, 2024
Maintains: Overweight
Price Target: $26 → $30
Current: $1.24
Upside: +2,319.35%
Apr 22, 2024
Initiates: Overweight
Price Target: $20
Current: $1.05
Upside: +1,804.76%
Mar 18, 2024
Maintains: Overweight
Price Target: $15 → $10
Current: $2.33
Upside: +329.18%
Feb 12, 2024
Initiates: Overweight
Price Target: $18
Current: $4.80
Upside: +275.00%
Oct 16, 2023
Maintains: Overweight
Price Target: $30 → $25
Current: $1.41
Upside: +1,673.05%
May 23, 2023
Downgrades: Neutral
Price Target: $15 → $1.75
Current: $3.05
Upside: -42.62%
Dec 20, 2022
Maintains: Overweight
Price Target: $18 → $20
Current: $22.81
Upside: -12.32%
May 5, 2022
Downgrades: Neutral
Price Target: $25 → $1.5
Current: $1.00
Upside: +49.99%
Mar 10, 2022
Maintains: Overweight
Price Target: $240 → $200
Current: $7.48
Upside: +2,573.80%
Jun 21, 2021
Initiates: Overweight
Price Target: $35
Current: $5.25
Upside: +566.67%
Mar 25, 2021
Initiates: Overweight
Price Target: $60
Current: $1.47
Upside: +3,981.63%
Apr 7, 2020
Maintains: Overweight
Price Target: $28 → $18
Current: $2.60
Upside: +592.31%